Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Incyte (Nasdaq:INCY) has announced an equity inducement award granted to Lee Heeson, the company's new Executive Vice President, Incyte International. The award, approved by the compensation committee of Incyte's Board of Directors, is in accordance with Nasdaq Listing Rule 5635(c)(4).
Mr. Heeson received 26,447 restricted stock units (RSUs) with a grant and vesting commencement date of October 1, 2024. The RSUs will vest in four equal installments of 25% each on the first four anniversaries of the vesting commencement date, contingent upon Mr. Heeson's continued service with Incyte on each vesting date.
Incyte (Nasdaq:INCY) ha annunciato un premio di incentivazione azionaria concesso a Lee Heeson, il nuovo Vicepresidente Esecutivo, Incyte International. Il premio, approvato dal comitato per la remunerazione del Consiglio di Amministrazione di Incyte, è conforme alla Regola 5635(c)(4) delle quotazioni Nasdaq.
Il Sig. Heeson ha ricevuto 26.447 unità di azioni vincolate (RSU) con una data di concessione e inizio della vestizione fissata al 1 ottobre 2024. Le RSU matureranno in quattro rate uguali del 25% ciascuna nei primi quattro anniversari della data di inizio di maturazione, a condizione che il Sig. Heeson continui a servire in Incyte in ciascuna data di maturazione.
Incyte (Nasdaq:INCY) ha anunciado un premio de incentivos en acciones otorgado a Lee Heeson, el nuevo Vicepresidente Ejecutivo de Incyte International. El premio, aprobado por el comité de compensación de la Junta Directiva de Incyte, está de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
El Sr. Heeson recibió 26,447 unidades de acciones restringidas (RSUs) con una fecha de concesión y comienzo de adquisición el 1 de octubre de 2024. Las RSUs se adquirirán en cuatro cuotas iguales del 25% cada una en los primeros cuatro aniversarios de la fecha de inicio de adquisición, sujeta a que el Sr. Heeson continúe prestando sus servicios a Incyte en cada fecha de adquisición.
Incyte (Nasdaq:INCY)는 Lee Heeson을 회사의 새로운 부사장으로 임명하며 주식 유인 보상을 발표했습니다. 이 보상은 Incyte 이사회의 보상위원회에서 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 진행됩니다.
Heeson 씨는 26,447 주식 제한 단위(RSU)를 수여받았으며, 부여 및 보장 시작일은 2024년 10월 1일입니다. RSU는 보장 시작일의 첫 네 번째 기념일에 각각 25%씩 네 번에 걸쳐 보장되며, 이는 Heeson 씨가 각 보장일에 Incyte에서 계속 근무해야 합니다.
Incyte (Nasdaq:INCY) a annoncé une prime d'incitation en actions accordée à Lee Heeson, le nouveau Vice-Président Exécutif d'Incyte International. La prime, approuvée par le comité des rémunérations du conseil d'administration d'Incyte, est conforme à la Règle de Cotation 5635(c)(4) de Nasdaq.
M. Heeson a reçu 26 447 unités d'actions restreintes (RSU) avec une date de concession et de début d'acquisition fixée au 1er octobre 2024. Les RSU seront acquises en quatre versements égaux de 25 % chacun aux quatre premiers anniversaires de la date de début d'acquisition, sous réserve que M. Heeson continue de servir chez Incyte à chaque date d'acquisition.
Incyte (Nasdaq:INCY) hat eine Aktienanreizprämie für Lee Heeson, den neuen Executive Vice President von Incyte International, bekannt gegeben. Die Prämie, die vom Vergütungsausschuss des Vorstands von Incyte genehmigt wurde, erfolgt gemäß Nasdaq Listungsregel 5635(c)(4).
Herr Heeson erhielt 26.447 eingeschränkte Aktieneinheiten (RSUs) mit einem Gewährungs- und Vesting-Beginn am 1. Oktober 2024. Die RSUs werden in vier gleichen Raten von 25% jeweils an den ersten vier Jahrestagen des Vesting-Beginns erworben, vorausgesetzt, Herr Heeson bleibt an jedem Vesting-Datum weiterhin bei Incyte tätig.
- Appointment of new Executive Vice President for Incyte International, indicating potential for international growth
- Equity inducement award aligns new executive's interests with company performance and shareholder value
- None.
Mr. Heeson received an award of 26,447 restricted stock units (RSUs) with a grant and vesting commencement date of October 1, 2024.
The RSUs vest as to
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003424838/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
What equity award did Incyte (INCY) grant to Lee Heeson?
When will Lee Heeson's RSUs from Incyte (INCY) vest?
What position did Lee Heeson take at Incyte (INCY)?
Under which Nasdaq rule did Incyte (INCY) grant the inducement award?
